Men's Health

"There are significant data examining the role of heat exposure to male sperm. However, none of it is very high quality and the data are murky at best," write James R. Craig, MD, MS; William Brant, MD; and James M. Hotaling, MD, MS.

A new approach to prostate cancer screening has been proposed by investigators who claim the idea of informed decision-making by primary care physicians is not working when it comes to PSA testing.

Other new products discussed in this article include a surgical training model, devices designed to improve prostate biopsy accuracy, an updated label and more.

Although a recent study of testosterone therapy does not fulfill the need for large-scale, randomized, controlled studies of the treatment, “it is very informative in several ways,” writes Arthur L. Burnett, II, MD, MBA.

Long-term testosterone therapy in hypogonadal men improves urinary function and erectile function compared with untreated controls, according to registry data from a single practice.

“I think we’re seeing more younger men coming in with erectile dysfunction, because there’s just a lot more publicity about the issue," one urologist said.

Other pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.

The risk of prostate cancer relapse after radical prostatectomy increases with lengthening delay between diagnosis and surgery. The impact, however, is significant only in high-risk patients, and even in those men, there may be a window of up to 12 months during which it may be relatively safe to postpone surgery, reported researchers from Milan, Italy.

In this interview, Daniel Shoskes, MD, discusses his evaluation of patients with scrotal pain, outlines his use of conservative treatments, and explains surgical approaches and how he decides whether to use them.

Urologist Henry Rosevear, MD, discusses actor Ben Stiller's recent blog post that credits PSA tests for saving his life after he was diagnosed with prostate cancer and the urologic community's surprising reaction to the article.

A new study revealing 91% of very low-risk and 74% of low-risk prostate cancer patients in Sweden choose active surveillance should be a benchmark for the use of the management strategy in the U.S. and elsewhere in the world, the study’s authors say.

Hypogonadism in men undergoing artificial urinary sphincter (AUS) implantation significantly increases the risk of cuff erosion, according to the results of a study presented by urologists from UT Southwestern Medical Center, Dallas.

Nearly 100% of patients with clinically localized prostate cancer, detected by PSA testing, survive at an average 10 years’ follow-up, regardless of whether they had active monitoring, radical prostatectomy, or radiotherapy, according to new study results.

In this video, M. Chad Wallis, MD, demonstrates the Cohen cross-trigonal ureteral reimplant, considered the most commonly performed open reimplant procedure.

In this video, Chester J. Koh, MD, shows key steps in a top-down approach without the use of stents for robot-assisted extravesical ureteral reimplantation.

Another study suggests that hemiablation with high-intensity focused ultrasound is a promising treatment for unilateral localized prostate cancer.

New research suggests that urologists can use the Decipher genetic test (GenomeDx Biosciences) to improve predictions of death risk from prostate cancer at10 years after prostatectomy.

Recent data show that a low-carbohydrate diet may have significant positive effects in men on hormonal therapy for prostate cancer, including metabolic effects. In this interview, study author Stephen J. Freedland, MD, discusses his group’s findings, ongoing research on diet and lifestyle changes in men with prostate cancer, and how he counsels patients.

In this video, Dr. Nicholas Kavoussi sits down with Dr. Arthur L. Burnett, II, of the Urology Times Editorial Council to discuss his 2016 AUA presentation, "Preoperative urine cultures for prosthetic urological surgery: What is the evidence?"

In this interview, Dr. David Albala sits down to discuss his award-winning poster on live-cell phenotypic biomarkers at the 2016 AUA with Urology Times Editorial Consultant, Dr. J. Brantley Thrasher.

Three urologists give their take on the frequency of patients presenting with prostate cancer.

Urologist Henry Rosevear, MD discusses his thoughts on PSA screening and the recent increase in patients presenting with metastatic disease.

Although various calculators are available for predicting biopsy results in men with prostate cancer being managed by active surveillance, a novel model developed by researchers at Johns Hopkins University is unique for its ability to predict a patient’s “true cancer state”; ie, the Gleason score that would be assigned on whole-gland analysis after radical prostatectomy.

As interest in using multiparametric MRI as a diagnostic tool for prostate cancer increases, urologists should know that a negative mpMRI does not rule out significant prostate cancer, researchers advised at the AUA annual meeting in San Diego.

A slow breathing technique guided by an iOS application was able to reduce the occurrence of vasomotor symptoms in a small study of prostate cancer survivors treated with androgen deprivation therapy.

Clinical outcomes of men with metastatic castration-resistant prostate cancer treated with enzalutamide (XTANDI) after chemotherapy correlate with health-related quality of life both at treatment initiation and its change longitudinally, researchers reported at the American Society of Clinical Oncology annual meeting in Chicago.

A treatment system that uses steam to ablate prostate tissue (Rezūm, NxThera, Inc.) can be considered as a first-line therapy for the treatment of lower urinary tract symptoms secondary to BPH, say investigators from a non-randomized multicenter pilot study with 2-year duration of successful outcomes.

A bladder cancer drug-device combination, a localized prostate cancer agent, and a new surgical robot are among other treatments in the pipeline discussed in this round-up.

Steven Lamm, MD and Darren Sultan, BA look at this and several other misconceptions.